# Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

> **NCT07523737** · PHASE2 · RECRUITING · sponsor: **Beijing Tongren Hospital** · enrollment: 43 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma (PCNSL)
- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** PD-1 / PD-L1 monoclonal antibody
- **DRUG:** XPO1 inhibitor

## Key facts

- **NCT ID:** NCT07523737
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07523737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07523737, "Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07523737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*